Overview

The March jobs report revealed a modest gain of 60,000 jobs, while the unemployment rate held steady at 4.4%. The ongoing US-Israel conflict with Iran has disrupted global energy supplies, driving up costs and creating uncertainty in hiring. Healthcare rebounded after strike-related losses in February, but rising oil prices and AI-driven job cuts pose new challenges. Economists predict further strain on discretionary spending and employment sectors as the conflict continues.

The Trump administration has announced new tariffs targeting pharmaceutical companies unless they agree to lower U.S. drug prices. Major drugmakers have secured agreements to avoid these tariffs by committing to "most-favored-nation" pricing and offering discounts through the TrumpRx.gov platform. These deals aim to align U.S. drug prices with those in developed nations, boost domestic manufacturing, and ensure significant investments in the U.S. pharmaceutical sector.

President Trump addressed the nation, signaling the winding down of U.S. involvement in the Iran war. The conflict, which has disrupted global oil markets and economic stability, is approaching its end, with Trump urging other nations to take responsibility for the Strait of Hormuz. Oil prices fluctuated during the announcement, while stock futures declined amidst uncertainty about the timeline for resolution. The president's remarks highlighted key economic impacts and geopolitical considerations as the war enters its final stages.

Eli Lilly's new oral weight-loss pill, Foundayo, has received FDA approval, intensifying competition with Novo Nordisk in the obesity treatment market. Foundayo offers the convenience of daily dosing without food or water restrictions, a key advantage over rival treatments. Analysts predict strong market uptake and significant sales growth for Lilly, with Foundayo poised to challenge Novo's Wegovy in the rapidly expanding obesity drug market.